A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma

Trial Profile

A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2016

At a glance

  • Drugs Apatorsen (Primary) ; Cisplatin; Gemcitabine
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Acronyms Borealis-1
  • Sponsors OncoGenex Technologies
  • Most Recent Events

    • 12 Nov 2015 According to an OncoGenex media release, results from this trial will be presented at the 7th European Multidisciplinary Meeting on Urological Cancers (EMUC 2015).
    • 28 Sep 2015 According to an OncoGenex media release, results from this trial were presented at the 2015 European Cancer Congress
    • 13 Jul 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top